Roche More Than Optimistic On Its Diagnostic Business, Will Not Reduce Prices Despite Roadblocks

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swiss drugmaker Roche Holding (ROG.VX) expects sales from its diagnostic division to grow faster in the United States than the market trend and it will not reduce prices despite reimbursement cuts in the U.S. health programme, an executive said. In April, the U.S. released final reimbursement rates for 2015 Medicare Advantage plans, which insurers and Wall Street analysts say represents a cut of about 3 percent. That comes after a year in which the government cut payments by about 6 percent.

Help employers find you! Check out all the jobs and post your resume.

Back to news